Learn

How Clinical Trials Work and How to Look One Up

Advertiser and Editorial Disclosures

Advertiser Disclosure

Wellness Pro News is supported by advertising. Some links and placements on this site are paid, and we may earn revenue when readers interact with them. Advertising never determines which topics we cover, which products we mention, or the conclusions our writers reach. Paid placements are labeled where they appear.

Editorial Disclosure

Our articles are researched and written by our editorial team and reviewed before publication. Health claims are checked against peer-reviewed research and recognized medical authorities, and we update articles when the evidence changes. Nothing on this site is medical advice or a substitute for care from a qualified clinician.

Emma Pollner

Emma Pollner, PhD, Clinical Research

How Clinical Trials Work and How to Look One Up

News stories often mention a "Phase 2 trial" or a "double-blind study" without explaining the terms. This guide covers the basics in plain words. It explains what a clinical trial is, how it differs from an observational study, what the four phases are for, and how randomization, placebos and blinding work. It also covers informed consent and ethics review, then walks through looking up a study record on ClinicalTrials.gov, the public registry run by the US National Library of Medicine.

What a clinical trial is

The National Institute on Aging (NIA) describes clinical research as "the study of health and illness in people." It splits that research into two main types.

Clinical trials are research studies that test a medical, surgical, or behavioral intervention in people. Researchers give participants something, or ask them to do something, and then measure what happens.

Observational studies work differently. In the NIA's words, they "monitor people in normal settings." Nothing is assigned or tested. Researchers watch, measure and record.

The four phases

Trials of new drugs usually move through a series of phases. Each phase asks a different question, and each tends to involve more people than the one before. The table below uses the participant numbers and purposes given on the Food and Drug Administration (FDA) page Step 3: Clinical Research, which is marked as current as of January 4, 2018.

Phase Purpose (FDA) Study participants (FDA)
Phase 1 Safety and dosage 20 to 100 healthy volunteers or people with the disease/condition
Phase 2 Efficacy and side effects Up to several hundred people with the disease/condition
Phase 3 Efficacy and monitoring of adverse reactions 300 to 3,000 volunteers who have the disease or condition
Phase 4 Safety and efficacy Several thousand volunteers who have the disease/condition

Official pages do not all give the same figures. The NIH basics page, last reviewed April 24, 2025, describes Phase I as a small group of 20 to 80 people, Phase II as 100 to 300, and Phase III as 1,000 to 3,000. These are typical ranges, not fixed rules.

Phase 4 is different from the rest. According to the NIA, a Phase 4 trial takes place after the FDA approves the drug or device. It tracks safety and effectiveness in larger groups over time.

Randomization, control groups and blinding

These three terms describe how a trial tries to produce a fair comparison.

Randomization

The NIH defines randomization as "the process by which treatments are assigned to participants by chance rather than by choice." The aim is to avoid bias.

Control groups and placebos

The NIA explains that participants may be assigned by chance to a treatment group or a control group. The treatment group gets the intervention being tested. The control group does not. The control group gives researchers a baseline for comparison.

Some control groups receive a placebo. The NIH describes a placebo as "an inactive product that resembles the test product, but without its treatment value." The same page says placebos are not used when going without effective therapy would put participants at risk, and that participants are told before enrolling if a placebo is part of the study.

Blinding

Blinding means keeping group assignments hidden so that expectations do not shape the results. The NIH describes two common forms. In a single-blind study, participants are not told what they are being given, but the research team knows. In a double-blind study, neither the participants nor the research team are told.

Informed consent and ethics review

Informed consent

The HHS Office for Human Research Protections (OHRP) says in its Informed Consent FAQs that the process has three key features: disclosing the information needed to make an informed decision, helping people understand what has been disclosed, and promoting the voluntariness of the decision about whether to take part.

Federal regulations at 45 CFR 46.116(a) list basic elements that must be covered. According to OHRP, these include a statement that the study involves research, its purposes, the expected duration and the procedures. They also include foreseeable risks or discomforts, expected benefits, how confidentiality is handled, and whom to contact with questions. The consent information must state that participation is voluntary and that a person may stop at any time without penalty or loss of benefits.

OHRP calls consent "an ongoing exchange of information" between the investigator and the participant. It continues after enrollment. The same FAQs say that paying research participants is generally acceptable, provided payment is just and fair and not so large that it unduly influences the decision.

The Institutional Review Board

An Institutional Review Board (IRB) is, in the NIH's words, "an independent committee that consists of physicians, statisticians, and members of the community." It reviews research before a study starts and while it proceeds, to protect the rights and safety of participants. The NIH notes that most, but not all, clinical trials in the United States are approved and monitored by an IRB.

How to look up a study on ClinicalTrials.gov

ClinicalTrials.gov is described in a National Library of Medicine (NLM) fact sheet dated October 2023 as the world's largest database of privately and publicly funded clinical studies. The NLM, part of the National Institutes of Health, runs it. The information in each record is provided by the sponsor or investigator of the study. The NIH defines sponsors as the people, institutions, companies, government agencies or other organizations responsible for initiating, managing or financing a trial.

The fact sheet also carries an important caution: "Listing a study does not mean it has been evaluated by the U.S. Federal Government."

A 2024 NLM Technical Bulletin describes how records are laid out on the current site. These steps follow that layout.

  1. Go to ClinicalTrials.gov and search for a topic. The NIH page Finding a Clinical Trial links to the site's own search help.
  2. Open a record. It opens on the Study Details tab, which shows the information the sponsor or investigator supplied at registration.
  3. Use the navigation menu on the left side to jump between sections such as Study Overview, Contacts and Locations, Participation Criteria and Publications. A section appears only if information was provided.
  4. Read Participation Criteria. The NIH explains that factors allowing someone to take part are called inclusion criteria and factors that rule someone out are called exclusion criteria. They can include age, sex, treatment history and other medical conditions.
  5. Check Contacts and Locations to see where the study is being conducted and whom to contact with questions.
  6. Look at the results tab. A Results Posted tab appears only for studies with summary results. Otherwise the tab reads "Results Not Posted."

Anyone with a health condition or specific needs, or anyone thinking about taking part in a study, should talk to their own clinician first, as the NLM fact sheet advises.

Frequently asked questions

Is a study listed on ClinicalTrials.gov approved by the government?

No. The NLM states that listing a study does not mean it has been evaluated by the US Federal Government. Sponsors and investigators submit the information for their own studies.

Does every clinical trial have an IRB?

Not every one. The NIH says most, but not all, clinical trials in the United States are approved and monitored by an IRB. It suggests asking the sponsor or research coordinator whether a study was reviewed by one.

Can a participant leave a trial after signing a consent form?

Yes. The NIH states that taking part is voluntary and that a participant can leave the study at any time. OHRP adds that stopping carries no penalty or loss of benefits.

Sources

All sources accessed November 16, 2026.

Last edited on
Emma Pollner
Emma Pollner

PhD, Clinical Research

Emma Pollner, PhD, has a background in clinical research. She writes and reviews our coverage of health research. LinkedIn: linkedin.com/in/emma-pollner

Was this article helpful? Let us know!